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1  | INTRODUC TION
One challenge of cancer immunotherapy is understanding the 
complex regulatory interactions between effector and target cells. 
Natural killer (NK) cells are unique innate lymphocytes that target 
viral infections and tumor cells. Their functions as effector cells 
include cytokine production, such as interferon- gamma (IFN- γ), 
exocytosis of cytotoxic granules containing granzyme B, and direct 
killing of target cells through Fas ligands and tumor necrosis factor 
(TNF)- related apoptosis- inducing ligand pathways.1-6 NK cells also 
produce chemokines including RANTES (regulated on activation, 
normal T- cell expressed and secreted) that induce T- cell migration 
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Abstract
Augmentation of natural killer (NK) cell cytotoxicity is one of the greatest challenges 
for	cancer	immunotherapy.	Although	histidine-	rich	glycoprotein	(HRG),	a	75-	kDa	gly-
coprotein with various immunomodulatory activities, reportedly elicits antitumor im-
munity, its effect on NK cell cytotoxicity is unclear. We assessed NK cell cytotoxicity 
against	K562	cells.	We	also	measured	concentrations	of	cytokines	and	granzyme	B	in	
the	cell	supernatant.	The	proportion	of	CD56bright NK cells and NK cell surface PD- 1 
expression was assessed with flow cytometry. The neutralizing effects of anti- C- type 
lectin- like receptor (CLEC) 1B against HRG were also measured. NK cell morphologi-
cal changes were analyzed via confocal microscopy. HRG significantly increased NK 
cell	cytotoxicity	against	K562	cell	lines.	HRG	also	increased	the	release	of	granzyme	
B	and	the	proportion	of	CD56bright NK cells. Further, HRG was able to decrease NK 
cell surface PD- 1 expression. The effects of HRG on NK cells were reversed with anti- 
CLEC- 1B antibodies. Additionally, we confirmed NK cell nuclear morphology and F- 
actin distribution, which are involved in the regulation of cytotoxic granule secretion. 
Because both PD- 1 and CLEC- 1B are associated with prognosis during malignancy, 
HRG incorporates these molecules to exert the antitumor immunity role. These facts 
indicate the potential of HRG to be a new target for cancer immunotherapy.
K E Y W O R D S
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and collaboratively kill target cells.7 A recent study found that 
programmed- death- 1 (PD- 1), an inhibitory checkpoint molecule, is 
expressed on NK cells. Given this, the regulation of PD- 1 expres-
sion on NK cells might provide therapeutic potential for antitumor 
immunotherapy.3
Histidine-	rich	glycoprotein	(HRG)	is	a	75-	kDa	glycoprotein	pro-
duced by the liver. Plasma levels of HRG are maintained at approx-
imately 1 μmol/L, with a relatively rapid turnover.8,9 Because of its 
multidomain, three- dimensional structure, HRG binds a variety of 
molecules such as heparin, fibrinogen, and heme,9 which facilitate 
numerous modulatory activities, such as cell adhesion, angiogenesis, 
and thrombosis.10-12 Researchers have hypothesized that decreased 
plasma levels of HRG are responsible for the development of pulmo-
nary fibrosis, preeclampsia, and sepsis.13,14 In septic pathophysiol-
ogy, the rapid decrease in plasma HRG might diminish its regulatory 
effects on neutrophils, vascular endothelial cells, and erythrocytes, 
leading to impaired passage of neutrophils through capillary vessels. 
It may also cause injury to vascular endothelial cells via the pro-
duction of reactive oxygen species by adhered neutrophils and the 
formation of immune- thrombosis.13-19 Thus, physiological concen-
trations of HRG in plasma might maintain the quiescence of circu-
lating neutrophils preventing the uncontrolled activation of vascular 
endothelial cells and thrombus formation.18 Moreover, plasma HRG 
is markedly decreased in septic patients in intensive care units, and it 
is superior to procalcitonin and presepsin as a biomarker in predict-
ing sepsis.14 In addition, HRG might potentiate the antitumor effects 
of tumor- associated macrophages via antiangiogenic effects.20,21
Some researchers suggest that NK cell- mediated cytotoxicity is 
augmented by various therapeutic agents and peptides.22-30 Among 
them, lenalidomide, an immunomodulatory drug for multiple my-
eloma, appears to indirectly restore NK cell function by inducing 
IFN- γ secretion, facilitating actin remodeling, and modulating PD- 1/
PD- L1 interactions.31,32 HRG inhibits tumor growth by inducing the 
migration of macrophages, cytotoxic T- cells (CTLs), and NK cells 
through the downregulation of placental growth factor.33 However, 
receptors of HRG and the exact mechanisms associated with the ef-
fects of HRG on NK cell cytotoxicity have not yet been elucidated.
C- type lectin- like receptors (CLECs) comprise a diverse family of 
transmembrane pattern recognition receptors expressed primarily on 
myeloid cells.34 Their functions include intercellular communication, 
host defense against infection, cancer immunity, and the mainte-
nance of different homeostatic responses.35 CLEC- 1A is a represen-
tative CLEC, and its encoding gene is closely linked to the NK gene 
complex.34 NK cells express a variety of functional CLEC superfamily 
receptors.36 Notably, CLEC- 1B, an immunoreceptor tyrosine- based 
activation motif (ITAM)- containing receptor, formerly known as CLEC- 
2, has been extensively researched based on its immunomodulatory 
functions. CLEC- 1B is linked to inflammation during sepsis, thrombo-
sis, and cancer immunity.37-40 Wang et al reported that CLEC- 1B might 
suppress AKT signaling and cancer cell invasiveness.40 More recently, 
it was suggested that CLEC- 1B expression levels can predict outcome 
for certain cancers.37 These reports make CLEC- 1B a fascinating ther-
apeutic target when considering antitumor immunity.
Here, we hypothesized that the inhibitory effects of HRG on tu-
mors could be attributed to its direct immunomodulatory effects on 
NK cells through the augmentation of cytokine production and mod-
ulation of PD- 1 expression. We also anticipated that CLEC, especially 
CLEC- 1B, might be a potential receptor for HRG. The purpose of this 
study was to examine whether HRG enhances NK cell cytotoxicity and 
regulates cytokine production by these cells through the stimulation 
of specific receptors, focusing on revealing molecular and pathological 
associations with antitumor immunity.
2  | MATERIAL S AND METHODS
2.1 | Antibodies and reagents
FITC- labeled anti- human CD279 (PD- 1; EH12.2H7), PE- labeled anti- 
human	 CD56	 (HCD56),	 PerCP-	labeled	 anti-	human	 CD3	 (SK7),	 and	
PE- labeled Mouse IgG1κ Isotype control (MOPC- 21) antibodies were 
purchased from BioLegend (San Diego, CA). Anti- human CLEC- 1 
goat polyclonal, anti- human CLEC- 2 goat polyclonal, and goat poly-
clonal control IgG antibodies were purchased from R&D Systems 
(Minneapolis,	MN).	 Phalloidin-	Alexa	 Fluor	 568,	 deoxyribonuclease	 I-	
Alexa Fluor 488, Hoechst33342, and Calcein- AM were obtained from 
Thermo Fisher Scientific (Waltham, MA). Recombinant human IL- 2 was 
purchased from Sigma- Aldrich (St. Louis, MO). For NK cell incubation, 
IL- 2 concentrations were adjusted to 200 U/mL in RPMI- 1640 medium.
2.2 | Cell culture
K562	cells	were	obtained	from	RIKEN	BioResource	Research	Center	
Cell Bank (Ibaraki, Japan). The cells were cultured in Dulbecco's 
modified Eagle's medium with 10% fetal calf serum, L- glutamine, and 
penicillin	and	streptomycin,	and	maintained	in	a	humidified	5%	CO2 
environment at 37°C.
2.3 | Isolation of peripheral blood mononuclear and 
NK cells from human blood
Peripheral blood mononuclear cells (PBMCs) were purified from 
healthy donors using Lymphoprep density gradient media (Alere 
Technologies AS, Oslo, Norway). In accordance with the ethical ap-
proval guidelines of Okayama University, written informed consent 
was	obtained	from	healthy	volunteers	(n	=	5),	and	blood	was	drawn	
from the cubital vein. Human primary NK cells were isolated using 
the EasySep Human NK Cell Enrichment Kit in accordance with 
the manufacturer's protocol (STEMCELL Technologies, Vancouver, 
Canada). The purity of NK cells was confirmed to be greater than 
90%	 by	 flow	 cytometric	 analysis	 using	 anti-	CD3	 and	 anti-	CD56	
monoclonal antibodies (data not shown).
2.4 | HRG purification from human plasma
HRG was purified from fresh frozen plasma samples obtained from 
the Japanese Red Cross Society as previously described.41
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2.5 | Cytotoxicity assays
NK cell- mediated cytotoxicity was measured using a lactate dehydro-
genase (LDH) Cytotoxicity Detection Kit (Takara Bio, Shiga, Japan). The 
extent of cytotoxicity was calculated according to the manufacturer's 
instructions. To establish the appropriate effector- to- target (E:T) ratios, 
K562	cells	and	PBMCs	were	incubated	for	6	hours	with	different	cell	
concentrations.	Next,	K562	cells	were	incubated	with	either	PBMCs	at	
an	80:1	E:T	ratio	or	NK	cells	at	a	10:1	E:T	ratio	for	6	hours	with	5%	CO2 
at 37°C. NK cells were used after overnight incubation in RPMI- 1640 
medium with IL- 2. After this, cells were washed three times to com-
pletely remove IL- 2. Then, cells were suspended in RPMI1640 without 
phenol red and 1 μmol/L HRG, 1 μmol/L human serum albumin (HSA), 
or Hank's balanced salt solution (HBSS) were added to the mixtures as 
test	compounds.	After	incubation,	the	tubes	were	centrifuged	at	500g 
for 3 minutes. The supernatant was then used for the determination of 
LDH. Percent NK cell- mediated cytotoxicity was presented based on 
the	following	equation:	%	cytotoxicity	=	(experimental	value	−	effec-
tor	cell	spontaneous	LDH	release	−	K562	spontaneous	LDH	release)/
(K562	maximum	LDH	release	−	K562	spontaneous	LDH	release)	×	100.	
A background control value was subtracted from all values.
2.6 | Cytometric bead analysis (CBA)
Concentrations of IL- 2, IFN- γ, granzyme B, and RANTES in the cell 
supernatant were measured using Flex CBA kits according to the 
manufacturer's instructions (BD Biosciences, Franklin Lakes, NJ). In 
brief, isolated human NK cells were cultured in RPMI 1640 with or 
without	IL-	2	overnight.	NK	cells	and	K562	cells	were	cocultured	in	
RPMI1640 without phenol red with a 10:1 E:T ratio and 1 μmol/L 
HRG, 1 μmol/L HSA, or HBSS for 16 hours. Supernatants were then 
acquired	for	analysis	after	centrifugation	at	500g for 3 minutes.
2.7 | CD56bright and CD56dim NK cell identification 
by flow cytometry
NK	 cells	 were	 stained	with	 a	 PE-	labeled	 anti-	CD56	monoclonal	
antibody	 and	 separated	 into	 CD56bright	 and	 CD56dim groups by 
flow	cytometry.	Briefly,	NK	cells	were	cultured	overnight	with	5%	
CO2 at 37°C after purification with or without IL- 2. The cells were 
then	cocultured	with	K562	cells	at	a	10:1	E:T	ratio	 in	RPMI1640	
without	 phenol	 red.	 After	 1	 hour	 of	 incubation,	 CD56	 expres-
sion on NK cells was analyzed using a MACSQuant Analyzer 
and MACSQuantify Software 2.11 (Miltenyi Biotec, Bergisch 
Gladbach, Germany).
2.8 | Cell surface PD- 1 expression analysis
To elucidate the effects of HRG on PD- 1 expression on NK cells, 
these	cells	were	cultured	overnight	with	5%	CO2 at 37°C after purifi-
cation	with	or	without	IL-	2.	NK	cells	were	incubated	with	K562	cells	
in RPMI1640 without phenol red at a 10:1 E:T ratio in the presence 
of 1 μmol/L HRG, 1 μmol/L HSA, or HBSS for 4 hours. The cells were 
then	stained	with	FITC-	labeled	anti-	PD-	1	and	PE-	labeled	anti-	CD56	
antibodies for flow cytometric analysis using a MACSQuant Analyzer.
2.9 | Effects of anti- CLEC antibodies on the 
effect of HRG immunomodulation
Anti- CLEC- 1A, anti- CLEC- 1B polyclonal, and goat IgG control anti-
bodies were added to each group subjected to PD- 1 analysis. The 
analysis of NK cell surface PD- 1 expression was performed as de-
scribed	 for	 each	method.	For	 this,	 0.5	μmol/L	HRG	or	0.5	μmol/L 
HSA were added to each group. Anti- CLEC and control antibodies 
were added at a concentration of 10 μg/mL before coculture.
2.10 | Observation of NK cell 
morphological changes
To clarify the effects of HRG on NK cell morphology, the cells were 
incubated with HRG, HSA, or HBSS at 1 μmol/L for 4 hours after 
overnight stimulation with IL- 2- containing RPMI1640. Cell shape 
was observed by calcein staining as described previously.18 An IN 
Cell Analyzer 2000 System (GE Healthcare, Little Chalfont, UK) 
was used for observation. The data were analyzed using IN Cell 
Investigator Version 1.62 (GE Healthcare, Little Chalfont, UK).
2.11 | Observation of F- actin/G- actin distribution in 
NK cells
After overnight incubation with IL- 2, NK cells were cocultured with 
K562	at	a	10:1	E:T	ratio	 in	the	presence	of	HRG,	HSA,	or	HBSS	at	
1 μmol/L for 4 hours in RPMI1640. The cell suspensions were then 
gelatinized using Smear Gell (GenoStaff, Tokyo, Japan) on amino- 
propyltriethoxy silane (APS)- coated glass slides (Matsunami, Tokyo, 
Japan) according to the manufacturers’ instructions. Cells were 
then fixed with 4% paraformaldehyde. After fixation, the cells were 
treated with 0.1% triton- X- 100 for membrane permeabilization, 
followed	 by	 staining	 with	 Phalloidin-	Alexa568	 (F-	actin),	 DNase	 I-	
Alexa488 (G- actin), and DAPI (nuclei). Samples were observed with 
a confocal microscope (LSM780, Carl Zeiss, Oberkochen, Germany).
2.12 | Statistical analysis
Tukey- Kramer or one- way ANOVA tests were performed. Data are 
presented as mean values ± SEM. P-	values	<0.05	were	considered	
statistically significant. All statistical analyses were conducted using 
JMP Version 13 (SAS Institute, Cary, NC).
3  | RESULTS
3.1 | HRG augments NK cell- mediated cytotoxicity 
toward K562 cells
Cytotoxicity peaked with an 80:1 E:T ratio (Figure 1A). After 
confirming the appropriate E:T ratio, NK cell cytotoxicity was 
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assessed quantitatively by measuring LDH release in the super-
natants	 of	 NK	 and	 K562	 cell	 cocultures.	 To	 examine	 whether	
NK cell cytotoxicity was augmented in the presence of HRG, we 
first	 compared	 the	 cytotoxicity	 of	 PBMCs	 against	 K562	 cells.	
Based on these results, 1 μmol/L HRG significantly increased NK 
cell- mediated cytotoxicity compared to HBSS and HSA groups 
(Figure	 1A).	 Next,	 we	 cocultured	 purified	 NK	 cells	 with	 K562	
cells to rule out the possibility that HRG was effecting PBMCs 
other than NK cells. We observed a similar dose- dependent in-
crease in cytotoxicity; a significant effect was noted with a con-
centration of 1 μmol/L. Incubation with HBSS and HSA did not 
produce any effects (Figure 1B).
3.2 | Effects of HRG on cytokine production and 
granzyme B secretion from NK cells
To explore the mechanism through which HRG modulates NK cell 
cytotoxicity, we quantified the concentration of various cytokines in 
the supernatants of cocultures. For this, we cocultured freshly iso-
lated,	IL-	2-	activated	NK	cells	with	K562	cells	for	16	hours	to	quan-
tify granzyme B levels in the supernatants. HRG not only increased 
granzyme B secretion from NK cells but also stimulated the produc-
tion and release of IL- 2, IFN- γ, and RANTES (Figure 2). Collectively, 
these results suggested that HRG could augment NK cell cytotoxic-
ity through two different pathways, specifically direct toxicity and 
an indirect immunomodulatory effect via cytokine and chemokine 
production.
3.3 | HRG increases the proportion of CD56bright 
NK cells
NK	 cells	 exist	 as	 three	 subpopulations,	 specifically	 CD56bright, 
CD56dim,	 and	 CD56negative	 cells.	 Among	 them,	 CD56bright NK cells 
are considered potential cytokine- producing cells that play roles 
in various processes, including antitumor immunity.42 They also 
exert	 cytotoxic	 effects	 upon	 activation.	 In	 contrast,	 CD56dim NK 
cells mainly exert cytotoxic effects independent of cytokine pro-
duction.43 Therefore, we speculated that HRG might not only ac-
tivate	NK	cells	but	also	 induce	the	differentiation	of	CD56dim cells 
into	CD56bright cells. As expected, HRG significantly increased the 
population	 of	 CD56bright	 NK	 cells	 after	 coculture	 with	 K562	 cells	
(Figure 3A- C). The effects of HRG on promoting differentiation into 
CD56bright cells were also significant in groups not pretreated with 
IL-	2	 (Figure	3B).	Consistent	with	the	 increase	 in	the	CD56bright cell 
population,	the	percentage	of	CD56dim cells decreased in the HRG- 
treated group (Figure 3C).
3.4 | PD- 1 expression is decreased by 
HRG treatment
Because the extent of PD- 1 expression on the NK cell surface may 
be related to their cytotoxic activity, we performed flow cytometric 
analysis to quantify the PD- 1 expression level on NK cells. HRG also 
decreased NK cell surface PD- 1 expression, irrespective of IL- 2 pre-
treatment (Figure 4A- C).
3.5 | An anti- CLEC- 1B polyclonal antibody 
inhibits the effects of HRG on NK cell PD- 1 expression
Next, we hypothesized that CLEC- 1B, a C- type lectin- like recep-
tor that is expressed on NK cells, could be a HRG receptor on NK 
cells based on previous reports suggesting a relationship between 
CLEC- 1B and tumor immunity.35 Due to an abundance of potential 
epitopes, we used human anti- CLEC polyclonal antibodies to examine 
the effect of HRG on NK cell PD- 1 expression. Anti- CLEC antibod-
ies were used at 10 μg/mL to minimize the immunomodulatory ef-
fects of the antibodies themselves. We set out to determine if the 
anti- CLEC- 1B antibody could inhibit the effects of HRG on PD- 1 
F IGURE  1 Histidine-	rich	glycoprotein	(HRG)	augments	natural	killer	(NK)	cell-	mediated	cytotoxicity	toward	K562	cells.	Peripheral	blood	
mononuclear	cells	(PBMCs)	or	NK	cells	purified	from	the	peripheral	blood	of	healthy	volunteers	were	incubated	with	K562	cells.	Cytotoxicity	
was evaluated by measuring the extent of lactate dehydrogenase (LDH) release after the indicated incubation periods. (A) Cytotoxicity 
experiments	were	performed	by	incubating	PBMCs	with	K562	cells	in	RPMI1640	without	phenol	red	at	different	effector-	target	(E:T)	ratios	
for 6 hours in the presence of HRG (1 μmol/L), human serum albumin (HSA; 1 μmol/L), or control (Hank's balanced saline solution; HBSS). 
The results are the mean ± SEM of three determinations. †P	<	0.05	compared	to	HBSS.	(B)	Purified	NK	cells	were	incubated	with	K562	cells	
at a 10:1 E:T ratio for 6 hours in the presence of different concentrations of HRG, HSA (1 μmol/L, 0.1 μmol/L, 0.01 μmol/L, 0.00 1 μmol/L), or 
HBSS (0 μmol/L). The results are the mean ± SEM of four or six determinations. **P < 0.01, ***P < 0.001 compared to HRG at an E:T ratio of 
80:1. †P	<	0.05,	††P < 0.01 compared to HBSS. ‡P	<	0.05	compared	to	HSA
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F IGURE  2 Histidine- rich glycoprotein (HRG) increases the secretion of granzyme B and cytokines from natural killer (NK) cells. Purified 
NK cells were pretreated in the presence or absence of IL- 2 overnight at 37°C. After extensive washing, NK cells were incubated with 
K562	cells	in	RPMI1640	without	phenol	red	at	an	effector-	target	(E:T)	ratio	of	10:1	for	16	hours	at	37°C,	supernatants	were	collected	
for determining granzyme B (A) and cytokine concentrations (B–D). The results are the mean ± SEM of five experiments (A) and three 
experiments (B- D). **P < 0.01, ***P < 0.001 compared to Hank's balanced saline solution (HBSS). ††P < 0.01, †††P < 0.001 compared to human 
serum albumin (HSA)
F IGURE  3 Histidine-	rich	glycoprotein	(HRG)	increases	the	proportion	of	CD56bright	natural	killer	(NK)	cells	relative	to	CD56dim NK cells. 
Purified NK cells were pretreated in the presence or absence of IL- 2 overnight at 37°C. After extensive washing, NK cells were incubated 
with	K562	cells	in	RPMI1640	without	phenol	red	at	an	effector-	target	(E:T)	ratio	of	10:1	for	1	hour	in	the	presence	of	HRG	(1	μmol/L), human 
serum albumin (HSA; 1 μmol/L),	or	Hank's	balanced	saline	solution	(HBSS).	After	cells	were	stained	with	a	PE-	labeled	anti-	human	CD56	
antibody, flow cytometric analysis was performed with a MACSQuant Analyzer. (A) Representative images of the flow cytometric analysis 
of	CD56	expression	on	NK	cells.	CD56bright	and	CD56dim cell populations were circled and indicated with bold “B” and “D”, respectively. (B) 
Percentages	of	CD56bright	NK	cells	and	(C)	CD56dim NK cells were evaluated by flow cytometric analysis. The results are the mean ± SEM of 
three experiments. *P	<	0.05,	**P < 0.01 compared to HBSS. †P	<	0.05,	††P < 0.01 compared to HSA
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expression	by	flow	cytometric	analysis.	As	shown	in	Figure	5A,B,	the	
anti- CLEC- 1B antibody significantly inhibited this effect by suppress-
ing cell surface PD- 1 expression, whereas the effect of anti- CLEC- 1A 
was not significant.
3.6 | HRG induces morphological changes 
associated with compact nuclear shapes and actin 
distribution in NK cells
Finally, based on a previous report that HRG induces morphological 
changes in neutrophils, to a more spherical shape, which were found 
to be associated with functional alterations,18 we speculated that sim-
ilar effects could occur with NK cells. In addition, because the nuclear 
shape is associated with mechanical forces exerted by the cytoskel-
eton and because NK cell lytic granules are transported along F- actin 
fibers,44 we utilized a live cell imaging device and confocal microscopy 
to visualize morphological changes. In HRG groups, NK cell nuclei 
became significantly rounder compared to those in HBSS and HSA 
groups (Figure 6A- C). Based on fluorescent confocal microscopy anal-
ysis, we determined that F- actin staining was localized mainly to the 
plasma membrane in a circular pattern in the HRG group. In contrast, 
F- actin was observed as spots in HBSS and HSA groups (Figure 6D- E).
4  | DISCUSSION
Our data highlight the significance of HRG in augmenting NK 
cell cytotoxicity through several pathways in the following ways: 
(a) direct cytotoxicity via granzyme B release, (b) cytokine pro-
duction and release, (c) an increase in the relative proportion of 
CD56bright NK cells, (d) decreased expression of cell surface PD- 1, 
and (e) actin remodeling. Previous research suggested that HRG 
is related to antitumor immunity,20 but the exact mechanisms 
were	 unclear.	 Although	 CD56bright	 and	 CD56dim NK cells are 
both known to release cytokines and granzyme B, respectively, 
HRG	not	only	increased	the	relative	proportion	of	CD56bright NK 
cells, but also enhanced granzyme B secretion. This suggests 
that HRG functions to augment cytotoxic granule production in 
CD56dim cells, which primarily exert direct cytotoxic immunity,43 
while	 facilitating	 the	 transition	 of	 CD56dim	 to	 CD56bright cells. 
Previously,	it	was	reported	that	CD56bright NK cells are increased 
in the tumor microenvironment of several malignancies.42,45 
Infiltration by these cells was negatively correlated with tumor 
stage,	which	suggested	that	CD56bright NK cells might be impor-
tant for antitumor surveillance.45 Interestingly, our results sug-
gest that HRG both increases direct cytotoxic activity and the 
proportion	of	CD56bright NK cells. Therefore, it may be possible 
F IGURE  4 PD- 1 expression on natural killer (NK) cell surfaces is decreased after histidine- rich glycoprotein (HRG) treatment. Purified 
NK	cells	were	pretreated	in	the	presence	or	absence	of	IL-	2	overnight	at	37°C.	After	extensive	washing,	NK	cells	were	incubated	with	K562	
cells in RPMI1640 without phenol red at an effector- target (E:T) ratio of 10:1 for 4 hours in the presence of HRG (1 μmol/L), human serum 
albumin (HSA; 1 μmol/L), or Hank's balanced saline solutions (HBSS). After cells were stained with FITC- labeled anti- human PD- 1 and PE- 
labeled	anti-	human	CD56	antibodies,	flow	cytometric	analysis	was	performed	with	a	MACSQuant	Analyzer.	(A)	Representative	images	of	
the flow cytometric analysis of IL- 2 pretreated cells are shown to illustrate PD- 1 expression on NK cells. (B) Representative images of the 
flow cytometric analysis of cells without IL- 2 pretreatment. (C) PD- 1 expression on NK cells was determined by flow cytometric analysis. The 
results are the mean ± SEM of three experiments. *P	<	0.05,	***P < 0.001 compared to HBSS. ††† p < 0.001 compared to HSA
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F IGURE  5 An anti- CLEC1B polyclonal antibody inhibits the effect of histidine- rich glycoprotein (HRG) on natural killer (NK) cell surface 
PD-	1	expression.	IL-	2	pretreated	NK	cells	were	incubated	with	K562	cells	in	RPMI1640	without	phenol	red	in	the	presence	of	HRG	
(0.5	μmol/L),	human	serum	albumin	(HSA;	0.5	μmol/L), or Hank's balanced saline solution (HBSS). To evaluate the inhibitory effect of anti- 
CLEC antibodies, anti- CLEC- 1A and anti- CLEC- 1B human goat polyclonal antibodies (pAbs) were added to HRG groups (HRG + anti- CLEC- 
1A pAb or anti- CLEC- 1B pAb). The antibody concentration was 10 μg/mL for each. (A) Representative images of flow cytometric analysis 
to	evaluate	PD-	1	expression	on	NK	cells	in	the	presence	of	HRG	(0.5	μmol/L) with or without anti- CLEC- 1A or anti- CLEC- 1B pAbs. (B) The 
percentage of PD- 1- positive cells among NK cells was determined by flow cytometric analysis of each group. The results are the mean ± SEM 
of nine experiments. *P	<	0.05,	**P < 0.01 compared to HBSS. †††P < 0.001 compared to HSA. ‡P	<	0.05	compared	to	HRG+CLEC-	1B	pAb
F IGURE  6 Histidine- rich glycoprotein (HRG) induces natural killer (NK) cell nuclear morphological transformation and intracellular actin 
reorganization. Live cell morphological changes were analyzed using the In Cell Analyzer 2000 system. NK cell F- actin/G- actin distribution 
was analyzed by fluorescence staining and confocal microscopy (LSM780, Carl Zeiss, Oberkochen, Germany). All images were acquired at 
63	×	original	magnification	by	confocal	laser	microscope	at	room	temperature.	Images	were	analyzed	with	ZEN	lite	2012	64-	bit	version	Black	
edition (Carl Zeiss, Oberkochen, Germany). (A) Representative NK cell morphologies are shown after treatment with HRG (1 μmol/L), human 
serum albumin (HSA; 1 μmol/L), or Hank's balanced saline solution (HBSS) for 4 hours at 37°C. (B) Nuclear morphologies were objectively 
evaluated. The form factor represents nuclear roundness, for which a form factor of 1 indicates a perfect circle. (C) Nuclear chord ratio 
represents the ratios of nuclear long to short axes, with a chord ratio closer to 1 implying perfect roundness. NK cell nuclei were significantly 
rounder in the HRG group. The results are the mean ± SEM of 21 experiments. Scale bars, 10 μm. **P < 0.01 vs HBSS. †P	<	0.05,	††P < 0.01 
vs HSA. (D) NK cell F- actin/G- actin distribution was analyzed by fluorescence staining and confocal microscopy. (E) Representative optical 
sections	of	Z-	stack	images	of	NK	cells	treated	with	HRG	or	HSA.	F-	actin;	Phalloidin-	Alexa	Fluor	568	(Red),	G-	actin;	DNase	I-	Alexa	Fluor	488	
(Green),	nuclei;	DAPI	(Blue).	Representative	images	are	shown.	Scale	bars,	5	μm
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that HRG exerts antitumor activity by enhancing direct anti-
tumor killing and tumor immunosurveillance. In addition, we 
showed that HRG increases the secretion of RANTES, which is 
a chemokine known to regulate the CTL response. Combining 
these findings with previous research indicating that RANTES 
enhances antitumor immunity in in vivo models,46 we speculate 
that HRG not only confers NK cell- mediated antitumor immu-
nity but also induces the migration of CTLs to tumor cells via 
the activity of RANTES, which are released from NK cells. This 
hypothesis is supported by the present results confirming that 
HRG significantly enhances the cytotoxic effects of NK cells to-
ward	K562	cells.
PD- 1, a member of the co- signaling B7 family, plays a role in 
downregulating NK cell immunity against hematological tumors.47 
Previous research suggested that PD- 1 expression could be a marker 
of NK cell functional exhaustion in patients with Kaposi sarcoma.48 
Further, a recent report indicated that PD- 1 expression on NK cells 
is crucial for innate immune regulation against tumors.47 To our 
knowledge, no other endogenous factors have been shown to mod-
ulate PD- 1 expression on NK cells. Intriguingly, HRG dramatically 
decreased NK cell surface PD- 1 expression, which was associated 
with	 augmented	 cytotoxic	 activity	 against	 K562	 cells,	 a	 chronic	
myelocytic leukemia cell line. Because PD- 1- positive NK cells are 
suggested to be anergic, indicating functional exhaustion,48 the sup-
pression of a PD- 1 negative checkpoint in NK cells might lead to ele-
vated effector cell functions.
CLEC- 1B, which is expressed diversely on myeloid cells in-
cluding NK cells and platelets, is involved in various aspects of 
innate immune responses against infections and tumors.37,39,40 
Recently, CLEC- 1B expression has received attention for its 
prognostic value in some types of malignancies; specifically, low 
CLEC- 1B expression indicates poor prognosis.37 Moreover, a pre-
vious report suggested that CLEC- 1B might suppress tumor ag-
gressiveness via the phosphoinositide 3- kinase/AKT pathway.40 
Based on the previous finding that low CLEC- 1B and high PD- L1 
expression both indicate poor prognosis for malignancies, it is 
plausible that HRG, which functions via CLEC- 1B to suppress NK 
cell surface PD- 1 expression has an important role in oncologic 
immunotherapy.
We also revealed that HRG modulates the nuclear shapes of NK 
cells, such that they become rounder. Additionally, we discovered 
that HRG modulates F- actin distribution by inducing its precise ar-
rangement circumferentially below the cytoplasmic membrane. This 
change in F- actin distribution was previously observed in neutro-
phils,18 suggesting that HRG might exert its function on different 
myeloid cells in a similar fashion. Cell nuclear shapes are partially 
controlled by cytoskeletal tension, mainly induced by actin.49 
Rounder cell nuclei reportedly correspond to increased gene expres-
sion, which might reflect increased cell activity.49 F- actin remodeling 
is important for the regulation of cytotoxic granule secretion.32,44 
Notably, our data provide evidence that HRG also influences actin 
remodeling, which could establish streamlined cytotoxicity via lytic 
granule secretion, as well as cytokine production and possibly ele-
vated gene expression.
Overall, our results illuminate the diverse and significant effects 
of HRG on NK cell cytotoxicity, which was found to occur through 
various pathways, via CLEC- 1B. Figure 7 is a schematic overview of 
the hypothesized mechanism through which HRG modulates NK cell 
functions. Future studies should include: (a) a binding assay of HRG 
and CLEC- 1B, comparing the binding activity with that of a known 
ligand, such as podoplanin, (b) a study to investigate whether HRG 
activates NK cells through not only direct binding to the NK cells but 
also	by	influencing	the	crosstalk	between	NK	cells	and	K562	cells,	(c)	
a study to clarify the binding affinity of PD- 1 and HRG, and (d) a con-
firmation of the relationship between the antitumor effects of HRG 
and NK cell cytotoxicity in in vivo models. The fact that HRG modu-
lates NK cell granzyme B and cytokine production, PD- 1 expression, 
and morphology indicates its potential as a therapeutic target for 
antitumor immunity.
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